Discussion

Our previous study has shown that Ucn 2 suppresses LH secretion from monolayer cultured anterior pituitary cells of rats (23). In the present study, Ucn 2 increased expression of miR-325-3p in the anterior pituitary cells of rats. The present study has also demonstrated that miR-325-3p overexpression decreases intracellular LH contents and suppresses basal LH secretion and LH β-subunit 3'-UTR activity, and that miR-325-3p knockdown blocks Ucn 2-induced suppression of intracellular contents and secretion of LH. These results suggest that miRNA is involved in Ucn 2-induced suppression of LH biosynthesis and secretion. Our previous study has also revealed that mRNA expression and secretion of Ucn 2 in the pituitary are increased by CRF *in vitro* (20) and by immobilization stress *in vivo* (21), and that the increases of mRNA expression and secretion of Ucn 2 in immobilization stress are blocked by anti-CRF IgG *in vivo* (21), suggesting that stress-induced CRF induces Ucn 2 secretion. Furthermore, we have shown that stress-induced suppression of LH secretion is blocked partially by anti-Ucn 2 IgG *in vivo* (21). Considered together with these previous findings, the results of the present study suggest that stress-induced Ucn 2 secretion causes an increase in miR-325-3p expression in the pituitary, which in turn suppresses LH β-subunit translation and secretion.

We tested the effect of intravenous administration of Ucn 2 on LH secretion and miR-325-3p expression in the anterior pituitary of rats, and no significant changes in plasma LH or miR-325-3p

expression levels in the anterior pituitary were induced by peripheral administration of Ucn 2 at doses of 5 and 15 μg (data not shown). Since Ucn 2 suppresses and a CRF-R2 antagonist increases LH secretion in the monolayer culture of rat anterior pituitary cells (23), these results suggest that factors which block or attenuate the inhibitory effect of Ucn 2 on LH secretion may be present in the peripheral circulation. CRF-binding protein (CRF-BP), which shows an intermediate affinity to Ucn 2, would be proposed as one of factors (12). There has been no study which shows CRF-BP in rat plasma. However, CRF-BP is likely to exist in peripheral blood of rats because it is synthesized by adrenomedullary chromaffin cells (5) and kupffer cells (4) of rats and CRF-BP is detected in human peripheral blood (9, 19). Therefore, Ucn 2 administered intravenously may bind to CRF-BP during peripheral circulation before reaching the gonadotrophs of the pituitary, and lose its inhibitory effect on gonadotrophs. Anyway, the Ucn 2 secreted by corticotrophs seems to act on gonadotrophs in a paracrine manner (23). Intracerebroventricular (icv) administration of Ucn 2 reportedly suppresses LH secretion in rats, although the site of action of Ucn 2 is unknown (17). Furthermore, icv administration of a selective CRF-R2 antagonist blocks restraint-, hypoglycemia-, or lipopolysaccharide-induced suppression of LH secretion in ovariectomized rats with estrogen replacement (16, 17). These findings suggest that CRF-R2 probably mediates stress-induced LH suppression at some site(s) other than the pituitary, and that Ucn 2 may play a role in the control of LH secretion under stress in the central nervous system.

Not only Ucn 2 but also Ucn 1, Ucn 3 and CRF bind to CRF-R2. However, since there has been no report showing that the anterior pituitary cells express Ucn 1 and Ucn 3, it seems that they have no physiological role in the regulatory mechanism of LH secretion at the pituitary level. Furthermore, we have shown that CRF has no effect on LH secretion in the monolayer cultured anterior pituitary cells of rats (21). Therefore, CRF, an endogenous ligand to CRF-R1, does not seem to affect miR-325-3p expression although 13 % of gonadotrophs express CRF-R1 (31).

miR-325-3p is reportedly expressed in brain, spleen and testis in rats (18). In addition to these tissues, we have found miR-325-3p is expressed in the anterior pituitary and that it is at least in part expressed in LH cells in the present study. Therefore, the miR-325-3p expressed in LH cells seems to play a suppressive role in the regulatory mechanism of LH biosynthesis. Although pituitary cells other than LH cells also express miR-325-3p, the physiological significance of miR-325-3p in the cells is unknown. In general, one miRNA has various target genes which may differ in each cell and/or tissues (14). Actually, mi-325-3p has more the 1000 target genes detected using the targetscan database. Further studies are needed to clarify the functions of miR-325-3p in other pituitary cells.

The present study has shown that overexpression and knockdown of miR-325-3p did not affect LH β-subunit mRNA expression although the intracellular content and secretion of Ucn 2 were influenced, suggesting that miR-325-3p inhibits translation but not transcription. These results are consistent with

our previous *in vitro* study showing that Ucn 2 suppresses LH secretion without changing LH β-subunit mRNA expression. By contrast, immobilization stress suppresses not only LH secretion but also LH β-subunit mRNA expression, and these changes are completely reversed by pretreatment with anti-CRF IgG while anti-Ucn 2 IgG significantly but partially blocked the immobilization-induced these changes (21). Taking these findings into consideration, it seems that some factor other than the Ucn 2/miR-325-3p system, which is induced by CRF, is involved in immobilization stress-induced suppression of LH β–subunit mRNA expression.

The human genome may encode thousands of miRNAs, which are abundantly expressed in many human cell types and may target about 60% of genes (3). These miRNAs target the 3'-UTR of mRNAs to inhibit translation. Recent studies have revealed that miRNAs have many physiological roles in endocrine and metabolic systems. Progesterone receptor translation and casein secretion are inhibited by miR-126-3p in mouse mammary epithelial cells (6). Toll-like receptor 4 is suppressed by miR-146a, and miR-146a reduces intracellular LDL cholesterol and secretions of IL-6, IL-8, chemokine ligand 2 and MMP-9 by inhibiting the toll-like receptor 4 signaling pathway (33). Since high glucose concentrations increase miR-410, miR-200a and miR-130a expression, these may be involved in glucose-stimulated insulin secretion in MIN6 cells (11). Concerning the hypothalamic-pituitary-gonadal axis, it has been shown that FSH down-regulates miR-29a and miR-30d expression, which are involved

in steroidogenic signaling pathways in cultured granulosa cells (34). Furthermore, it has been reported that GnRH increases miR-132 and miR-212, and that these are implicated in GnRH-stimulated cellular biochemical metabolic responses in LβT2 cells (35). However, the physiological role of miRNAs in pituitary hormone secretion has not been reported. The current study provides a new insight into understanding the function of miRNAs in regulating pituitary hormones biosynthesis.

Although miRNA transcription is controlled by RNA polymerase II or III and primary miRNA is processed in the nucleus (2, 7, 15), little is known about the signaling pathways that control its expression. It was reported that protein kinase A (PKA) affects the Wnt signaling pathway, and inhibition of PKA-induced Wnt-β catenin signaling is mediated by miRNA expression (13). We have previously demonstrated that Ucn 2 activates PKA and MAPK in PC12 cells (22). Unfortunately, H-89 and Rp-cAMPs, both PKA inhibitors, failed to block Ucn 2-induced miR-325-3p expression, and miR-325-3p expression was unaffected by forskolin, a PKA activator (data not shown). Further studies are needed to clarify other intracellular signaling pathways leading to Ucn 2-induced increases in miR-325-3p expression.

In summary, the present study suggests that miR-325-3p is involved in stress-induced suppression of LH secretion, and that Ucn 2 plays a role in increasing the expression of miR-325-3p. This is a newly identified pathway underlying regulation of LH secretion. These results may increase understanding of

the molecular mechanisms involved in development of stress-induced gonadal dysfunction.

Acknowledgement

We are grateful to Shino Inada and Mitsue Iketani for their excellent technical assistance.

References

1. **Arai K, Ohata H, and Shibasaki T.** Non-peptidic corticotropin-releasing hormone receptor type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: evidence that an increase in arousal induced by stress is mediated through CRH receptor type 1. *Neurosci Lett* 255: 103-106, 1998.

2. **Borchert GM, Lanier W, and Davidson BL.** RNA polymerase III transcribes human microRNAs. *Nat Struct Mol Biol* 13: 1097-1101, 2006.

3. **Carthew RW and Sontheimer EJ.** Origins and Mechanisms of miRNAs and siRNAs. *Cell* 136: 642-655, 2009.

4. **Charalampopoulos I, Androulidaki A, Minas V, Chatzaki E, Tsatsanis C, Notas G, Xidakis C, Kolios G, Kouroumalis E, Margioris AN, and Gravanis A.** Neuropeptide urocortin and its receptors are expressed in rat Kupffer cells. *Neuroendocrinology* 84: 49-57, 2006.

5. **Chatzaki E, Margioris AN, and Gravanis A.** Expression and regulation of corticotropin-releasing hormone binding protein (CRH-BP) in rat adrenals. *J Neurochem* 80: 81-90, 2002.

6. **Cui W, Li Q, Feng L, and Ding W.** MiR-126-3p regulates progesterone receptors and

involves development and lactation of mouse mammary gland. *Mol Cell Biochem*, 2011.

7. **Dieci G, Fiorino G, Castelnuovo M, Teichmann M, and Pagano A.** The expanding RNA polymerase III transcriptome. *Trends Genet* 23: 614-622, 2007.

8. **Findlay JK, Drummond AE, Dyson M, Baillie AJ, Robertson DM, and Ethier JF.** Production and actions of inhibin and activin during folliculogenesis in the rat. *Molecular and cellular endocrinology* 180: 139-144, 2001.

9. **Florio P, Imperatore A, Sanseverino F, Torricelli M, Reis FM, Lowry PJ, and Petraglia F.** The measurement of maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein improves the early prediction of preeclampsia. *J Clin Endocrinol Metab* 89: 4673-4677, 2004.

10. **Gharib SD, Wierman ME, Badger TM, and Chin WW.** Sex steroid hormone regulation of follicle-stimulating hormone subunit messenger ribonucleic acid (mRNA) levels in the rat. *J Clin Invest* 80: 294-299, 1987.

11. **Hennessy E, Clynes M, Jeppesen PB, and O'Driscoll L.** Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells. *Biochem Biophys Res Commun* 396: 457-462, 2010.

12. **Huising MO, Vaughan JM, Shah SH, Grillot KL, Donaldson CJ, Rivier J, Flik G, and Vale WW.** Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively

abrogate binding to CRF but not to urocortin 1. *J Biol Chem* 283: 8902-8912, 2008.

13. **Iliopoulos D, Bimpaki EI, Nesterova M, and Stratakis CA.** MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. *Cancer Res* 69: 3278-3282, 2009.

14. **John B, Enright AJ, Aravin A, Tuschl T, Sander C, and Marks DS.** Human MicroRNA targets. *PLoS Biol* 2: e363, 2004.

15. **Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, and Kim VN.** MicroRNA genes are transcribed by RNA polymerase II. *Embo J* 23: 4051-4060, 2004.

16. **Li XF, Bowe JE, Kinsey-Jones JS, Brain SD, Lightman SL, and O'Byrne KT.** Differential role of corticotrophin-releasing factor receptor types 1 and 2 in stress-induced suppression of pulsatile luteinising hormone secretion in the female rat. *J Neuroendocrinol* 18: 602-610, 2006.

17. **Li XF, Bowe JE, Lightman SL, and O'Byrne KT.** Role of corticotropin-releasing factor receptor-2 in stress-induced suppression of pulsatile luteinizing hormone secretion in the rat. *Endocrinology* 146: 318-322, 2005.

18. **Linsen SE, de Wit E, de Bruijn E, and Cuppen E.** Small RNA expression and strain specificity in the rat. *BMC Genomics* 11: 249, 2010.

19. **Lowry PJ.** Corticotropin-releasing factor and its binding protein in human plasma. *Ciba*

Found Symp 172: 108-115; discussion 115-128, 1993.

20. **Nemoto T, Iwasaki-Sekino A, Yamauchi N, and Shibasaki T.** Regulation of the expression and secretion of urocortin 2 in rat pituitary. *J Endocrinol* 192: 443-452, 2007.

21. **Nemoto T, Iwasaki-Sekino A, Yamauchi N, and Shibasaki T.** Role of urocortin 2 secreted by the pituitary in the stress-induced suppression of luteinizing hormone secretion in rats. *Am J Physiol Endocrinol Metab* 299: E567-575, 2010.

22. **Nemoto T, Mano-Otagiri A, and Shibasaki T.** Urocortin 2 induces tyrosine hydroxylase phosphorylation in PC12 cells. *Biochem Biophys Res Commun* 330: 821-831, 2005.

23. **Nemoto T, Yamauchi N, and Shibasaki T.** Novel action of pituitary urocortin 2 in the regulation of expression and secretion of gonadotropins. *J Endocrinol* 201:.105-114, 2009.

24. **Nolan T, Hands RE, and Bustin SA.** Quantification of mRNA using real-time RT-PCR. *Nat Protoc* 1: 1559-1582, 2006.

25. **Pakarinen P and Huhtaniemi I.** Gonadal and sex steroid feedback regulation of gonadotrophin mRNA levels and secretion in neonatal male and female rats. *J Mol Endocrinol* 3: 139-144, 1989.

26. **Pierce JG and Parsons TF.** Glycoprotein hormones: structure and function. *Annu Rev Biochem* 50: 465-495, 1981.

27. **Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, and Sawchenko PE.** Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. *Proc Natl Acad Sci U S A* 98: 2843-2848, 2001.

28. **Rivest S and Rivier C.** Central mechanisms and sites of action involved in the inhibitory effects of CRF and cytokines on LHRH neuronal activity. *Ann N Y Acad Sci* 697: 117-141, 1993.

29. **Rivier C and Rivest S.** Effect of stress on the activity of the hypothalamic-pituitary-gonadal axis: peripheral and central mechanisms. *Biol Reprod* 45: 523-532, 1991.

30. **Tran U, Zakin L, Schweickert A, Agrawal R, Doger R, Blum M, De Robertis EM, and Wessely O.** The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity. *Development* 137: 1107-1116, 2010.

31. **Westphal NJ, Evans RT, and Seasholtz AF.** Novel expression of type 1 corticotropin-releasing hormone receptor in multiple endocrine cell types in the murine anterior pituitary. *Endocrinology* 150: 260-267, 2009.

32. **Yamauchi N, Otagiri A, Nemoto T, Sekino A, Oono H, Kato I, Yanaihara C, and Shibasaki T.** Distribution of urocortin 2 in various tissues of the rat. *J Neuroendocrinol* 17: 656-663, 2005.

33. **Yang K, He YS, Wang XQ, Lu L, Chen QJ, Liu J, Sun Z, and Shen WF.** MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. *FEBS Lett* 585: 854-860, 2011.

34. **Yao N, Yang BQ, Liu Y, Tan XY, Lu CL, Yuan XH, and Ma X.** Follicle-stimulating hormone regulation of microRNA expression on progesterone production in cultured rat granulosa cells. *Endocrine* 38: 158-166, 2010.

35. **Yuen T, Ruf F, Chu T, and Sealfon SC.** Microtranscriptome regulation by gonadotropin-releasing hormone. *Molecular and cellular endocrinology* 302: 12-17, 2009.

Figure legends

Figure 1 miRNAs biding sites of LH β-subunit 3'-UTR sequence and expression of miR-325-3p in the anterior pituitary of rats

(A) Predicted miRNAs binding sites are underlined. Transcriptional termination codon is shown in bold. (B) Typical picture of combination of *in situ* hybridization of miR-325-3p (purple) and immunohistochemistry of LH β-subunit (brown) in the anterior pituitary is shown. Double-positive cells are indicated by arrows. Scale bar, 50 μm.

Figure 2 Effects of Ucn 2 on miR-325-3p expression in rat monolayer cultured anterior pituitary cells

(A) miR-325-3p expression in anterior pituitary cells treated with Ucn 2 at various concentrations ranging from 1 to 100 pM for 1 h. (B) Time course for miR-325-3p expression in anterior pituitary cells treated with 100 pM Ucn 2. The levels are shown as % of control. Data shown as mean ± SEM. *, $p<0.05$ compared to control. Eight wells were used for each treatment. cont, control.

Figure 3 Effect of anti-Ucn 2 IgG pretreatment on miR-325-3p expression in the anterior pituitary of immobilization-stressed rats

miRNA expression levels are shown as % of that in NRS IgG-injected non-stressed controls. N for each experimental group=5. *; p<0.05 compared to the non-stressed controls. non, non-stressed control group; NRS IgG, normal rabbit serum IgG-injected rats; anti-Ucn 2, anti-Ucn 2 IgG-injected rats; IMO, 90-min immobilization stress exposed group.

Figure 4 Effects of overexpression or suppression of miR-325-3p on LH secretion and LH β subunit mRNA expression *in vitro*

Cultured anterior pituitary cells were transfected with pBA-miR-325-3p, pBA-mock, pDecoy-miR-325-3p, or pDecoy-mock vectors. After 72 h, total RNA was extracted for northern blot analyses of miR-325-3p expression (A). After 72 h, each transfectant cells were treated with 100 pM Ucn 2 for 1 h and LH β-subunit mRNA expression (shown as % of control) (B) and intracellular contents and secretion of LH (C for pBA-miR325-3p and D for pDecoy-miR-325-3p) were determined. Data shown as mean ± SEM. *, p<0.05 compared to mock transfectants. Eight wells were used for each treatment.

Figure 5 Effects of overexpression of miR-325-3p on LH β-subunit 3'-UTR activity

(A) Sequences for LH β-subunit 3'-UTR ((pmir-Glo LHβ 3'UTR (WT) and pmir-Glo LHβ 3'UTR

(SC)), used in this study are shown. miR-325-3p binding site (underlined) is replaced with scramble mutation, which is not recognized by miR-325-3p. Transcriptional termination codon is shown in bold. (B) HEK293 cells were co-transfected with pmir-Glo LHβ 3'UTR (WT), pmir-Glo LHβ 3'UTR (SC) or pmir-Glo mock plasmid and pBA-miR-325-3p or pBA-mock plasmid. After 72 h, firefly and *Renilla* luciferase activities were assayed, and transfection efficiency was obtained by calculating their ratios. The levels are shown as % of pBA-mock transfectants. Data shown as mean ± SEM. *, p<0.05 compared to pBA-mock transfectants. Six wells were used for each assay.





Figure 1



Figure 2



Figure 3

A

pBA

mock

miR325-3p

pDecoy

mock

miR325-3p

B

LH β mRNA expression (mock=100)

0 50 100 150 200 250

mock | miR325-3p | mock | miR325-3p

pBA | pDecoy

C

intracellular LH (ng/ml)

0 2 4 6 8 10

*

control | Ucn 2 | control | Ucn 2

p BA mock | pBA-325-3p

D

0 2 4 6 8 10

*

*

control | Ucn 2 | control | Ucn 2

pDecoy-mock | pDecoy-325-3p

E

LH secretion (ng/ml)

0 2 4 6 8 10

*

p=0.07

control | Ucn 2 | control | Ucn 2

p BA mock | pBA-325-3p

F

0 2 4 6 8 10

*

control | Ucn 2 | control | Ucn 2

pDecoy-mock | pDecoy-325-3p

Figure 4

A

pmir-Glo LHβ 3'UTR (WT)



pmir-Glo LHβ 3'UTR (SC)



B



Figure 5

J. Biochem. 2012;151(2):119–128 doi:10.1093/jb/mvr134

JB THE JOURNAL OF BIOCHEMISTRY

JB Review

Structure, regulation and function of ghrelin

Received September 5, 2011; accepted October 20, 2011; published online October 31, 2011

Takahiro Sato[1,†], Yuki Nakamura[1], Yuki Shiimura[1], Hideko Ohgusu[1], Kenji Kangawa[2] and Masayasu Kojima[1,*]

[1]Institute of Life Science, Kurume University, Kurume 839-0864 and [2]National Cardiovascular Center Research Institute, Suita 565-8565, Japan

*Masayasu Kojima, MD, PhD, Molecular Genetics, Institute of Life Science, Kurume University, Hyakunen-kouen 1-1, Kurume 839-0864, Japan. Tel: +81(0)942-37-6313, Fax: +81(0)942-31-5212, email: mkojima@lsi.kurume-u.ac.jp

†Correspondence may also be addressed to Takahiro Sato, PhD, Molecular Genetics, Institute of Life Science, Kurume University, Hyakunen-kouen 1-1, Kurume 839-0864, Japan. Tel: +81(0)942-37-6313, Fax: +81(0)942-31-5212, email: satou_takahiro@kurume-u.ac.jp

Ghrelin is a stomach hormone that acts as an endogenous ligand of orphan G-protein-coupled receptor. Ghrelin is a 28-amino acid peptide existing in two major forms: *n*-octanoyl-modified ghrelin, which possesses an *n*-octanoyl modification on serine-3 and des-acyl ghrelin. Fatty acid modification of ghrelin is essential for ghrelin-induced growth hormone release from the pituitary and appetite stimulation. This acyl-modification of ghrelin is catalysed by ghrelin-*O*-acyl transferase recently identified. Despite the number of innovative advancements in this field of research, there are still many aspects of ghrelin function and biosynthesis process that remain to be clarified. Here, we review the current understanding of the structure, regulation and function of ghrelin; this review is intended for researchers who will be involved in this field in the future.

Keywords: acyl ghrelin/des-acyl ghrelin/GHSs/GHS-R/GOAT.

Abbreviations: ACTH, adrenocorticotropic hormone; AgRP, agouti-related protein; AMPK, 5′ AMP-activated protein kinase; ARC, arcuate nucleus; GH, growth hormone, GHRH, growth hormone releasing hormone; GHS, growth hormone secretagogue; GHS-R, growth hormone secretagogue receptor; GOAT, ghrelin-*O*-acyl transferase; GPCR, G-protein coupled receptor; IP_3, inositol 1,4,5-trisphosphate; MBOATs, the membrane-bound O-acyltransferases; MCFAs, medium-chain fatty acids; MCTs, medium-chain triacylglycerols; MTLRP, motilin-related peptide; NPY, neuropeptide Y; POMC, proopiomelanocortin; PRL, prolactin; 7TM, seven transmembrane domains.

History of Ghrelin Discovery

Kojima *et al.* (*1*) discovered ghrelin in 1999 as a 28-amino acid peptide from the rat stomach extracts. To understand why so many researchers were hunting for this hormone, and why the discovery took such a long time, we must go back to the identification of growth hormone secretagogues (GHSs).

It had been observed that some opioid peptide derivatives had weak growth hormone (GH)-releasing activity. In 1976, Bowers *et al.* (*2*) referred to these compounds as GHSs. Although the activity of early GHSs was very weak, many peptidyl derivatives with more potent GH-releasing activity were synthesized subsequently; including GHRP-6, first reported in 1984 (*3*). The non-peptide GHS L-692,429 was synthesized by Smith and colleagues (*4*) in 1993, suggesting the possibility of clinical use of GHSs because the non-peptide GHS is available for oral administration. Another non-peptide GHS, L-163,191 (MK-0677), was subjected to clinical trials, since it retained sufficient activity even when orally administered (*5*).

During this period, action of GHSs was gradually elucidated. Growth hormone releasing hormone (GHRH), the hormone that promotes GH secretion from GH-secreting cells in the anterior pituitary, acts on the GHRH receptor to increase intracellular cAMP, which serves as a second messenger (Fig. 1) (*6–10*). GHSs also act on a different receptor on GH-secreting cells in the anterior pituitary, increasing the intracellular Ca^{2+} concentration via an inositol 1,4,5-trisphosphate (IP_3) signal transduction pathway (Fig. 1). Growth hormone secretagogue receptor (GHS-R) was identified as a typical G-protein coupled receptor (GPCR) in 1996, and it was subsequently learned that GHSs stimulate phospholipase C, resulting in an increase in IP_3 and intracellular Ca^{2+} (*11*). GHS-R is expressed in the pituitary, hypothalamus and hippocampus; when it was discovered, this receptor was an orphan GPCR for which the natural ligand was not known (*11, 12, 13*). Therefore, a search for its endogenous ligand was actively undertaken using the orphan receptor strategy. Identification of the endogenous ligand was not easy, because it was mainly distributed in the stomach whereas GHS-R was mostly distributed in hypothalamus. Eventually, in 1999, ghrelin was identified as the endogenous ligand of GHS-R (*1*).

Structure of Ghrelin and of the Related Substances

Ghrelin

Ghrelin is a peptide consisting of 28 amino acids, and is unusual among peptide hormones of which Ser3 is *n*-octanoylated (Fig. 2a) (*1*). This modification, the first known case in mammals, is essential for ghrelin's activity (*1*).

The human ghrelin gene is localized on chromosome 3p25–26 (*14*). Both human and mouse ghrelin genes

© The Authors 2011. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved



Fig. 1 A second messenger of GHRH and GHSs. GHRH acts on the GHRH receptor to increase intracellular cAMP, which serves as a second messenger. On the other hand, GHSs have also been shown to act on a GHS-R, increasing intracellular Ca^{2+} concentration via an IP_3 signal transduction pathway.

comprise five exons (*15*, *16*). There are two different transcriptional initiation sites in the ghrelin gene; one occurs at −80 and the other at −555 relative to the ATG initiation codon, resulting in two distinct mRNA transcripts (transcript-A and transcript-B) (*15*, *17*). The 28 amino acids of the functional ghrelin peptide are encoded in exons 1 and 2.

In rat and mouse stomach, a second type of ghrelin peptide has been purified and identified as des-Gln14-ghrelin (*18*). In ghrelin genes of these rodents, the codon for Gln14 (CAG) is used as an alternative splice acceptor site to generate two different ghrelin mRNAs. One mRNA encodes the ghrelin precursor, and another encodes a des-Gln14-ghrelin precursor. Except for the deletion of Gln14, des-Gln14-ghrelin is identical to ghrelin. This type of ghrelin also retains the *n*-octanoic acid modification, and has the same activities and potency as ghrelin. However, the level of des-Gln14-ghrelin in the stomach is low. Bovine and ovine ghrelins are 27-amino acid peptides which, like rat des-Gln14 ghrelin, lack the Gln14 residue. In the genes encoding these ghrelins, there is only one AG splice acceptor site between exons 2 and 3, resulting in the production of only one mRNA, which gives rise to the 27-residue ghrelin.

The non-acylated form of ghrelin, des-acyl ghrelin, is also present at significant levels in both stomach and blood (*19*). However, des-acyl ghrelin can neither bind GHS-R nor exhibit GH-releasing activity in rats. Nonetheless, food intake is induced by des-acyl ghrelin, administered by intracerebroventricular injection, to the same extent as ghrelin (*20*). Because the genome database does not contain another GPCR that resembles GHS-R, it is possible that des-acyl ghrelin acts by mechanisms independent of a GPCR. Further study will be required in order to determine the physiological significance of des-acyl ghrelin.

Ghrelin has been identified in many species. The amino acid sequences of human, rat and mouse ghrelin precursors are shown in Fig. 2b. The amino acid sequences of mature ghrelins are well conserved across mammals, including human, rat, mouse, rhesus monkey, mongolian gerbil, cow, pig, sheep and dog (*1*, *16*, *21*, *22*). Specifically, the 10 amino acids in the NH_2-termini are identical, strongly suggesting that this NH_2-terminal region is necessary for the activity of ghrelin. Mammalian ghrelin has a variety of functions—to stimulate GH release, food intake, fat accumulation, etc.

Among birds, chicken ghrelin is composed of 26 amino acids, and possesses 54% sequence identity with human ghrelin. Chicken ghrelin is predominantly expressed in the stomach, where it is present in the proventriculus (*23*). Administration of chicken ghrelin increased plasma GH levels in both rats and chicks, indicating that the stimulatory effect of ghrelin on GH secretion is evolutionarily conserved (*23*). On the other hand, intracerebroventricular injection of chicken ghrelin or of KP-102, a synthetic GHS, strongly suppressed feeding in neonatal chicks during the 2-h post-injection period, whereas ghrelin strongly stimulates feeding in mammals. Furthermore, the suppressive effect of feeding by chicken and rat ghrelin was almost identical in neonatal chicks. Thus, it is possible that the mechanisms for feeding of the neonatal chick are different from mammals.

Among amphibians, bullfrog ghrelin contains either 27 or 28 amino acids due to the differential processing of the COOH-terminal Asn residue (*24*). Bullfrog ghrelin possesses 29% sequence identity to human ghrelin. The unique amino acid sequence feature of bullfrog ghrelin is Thr3, corresponding to Ser3 in the mammalian ghrelins; bullfrog Thr3 is also modified, either by *n*-octanoic or *n*-decanoic acid. Bullfrog ghrelin mRNA is predominantly expressed in the stomach. Bullfrog ghrelin stimulates the secretion of both GH and PRL in dispersed bullfrog pituitary cells with potency 2–3 orders of magnitude greater than that of rat ghrelin. Bullfrog ghrelin, however, was only minimally effective in elevating plasma GH levels following intravenous injection into rats. Thus, although the ability of ghrelin to induce GH secretion is evolutionarily conserved, the structural differences between orthologous ghrelins result in species-specific receptor binding.

Fish ghrelins have been identified in rainbow trout, eel, tilapia and goldfish (*25–29*). Ghrelin has four isoforms in rainbow trout and two molecular forms in eel. In tilapia, ghrelin Ser3 is modified by *n*-decanoic acid, and the COOH-terminal end of the peptide possesses an amide structure. The goldfish ghrelin gene consists of four exons and three short introns. As in other vertebrates, fish ghrelins are also predominantly detected in the stomach. In organ-cultured tilapia pituitary, the release of GH and PRL are stimulated by eel ghrelin at a dose of 0.1 nM, and by tilapia ghrelin at a dose of 10 nM. Intracerebroventricular injection of *n*-octanoylated goldfish ghrelin (residues 1–19) stimulated food intake in goldfish.

GHS-R

The human ghrelin receptor gene has also been identified on chromosome 3, at position q26–27 (*14*). Ghrelin receptor is a typical GPCR, with seven transmembrane domains (7TM); it is expressed as two distinct mRNAs (*11*). The first, GHS-R type 1a, encodes a 7TM GPCR with binding and functional properties consistent with its role as the ghrelin receptor. The other GHS-R mRNA, type 1b, is produced by



Fig. 2 (a) Structure of human ghrelin and the modification process of octanoic acid by GOAT. In rats, the 11th residue is lysine (K) and the 12th is alanine (a). (b) Amino acid sequences of ghrelin precursors in human, rat and mouse. Identical amino acids are coloured in grey. The asterisk shows the position of acyl-modified Ser3.

alternative splicing. The GHS-R gene consists of two exons; the first exon encodes TM1–TM5, and the second exon encodes TM6–TM7. Type 1b is derived from the first exon alone, and encodes only five of the seven predicted TM domains. The type 1b receptor is thus a COOH-terminal truncated form of the type 1a receptor, and is physiologically inactive.

Among GPCRs, ghrelin receptor is most similar to the motilin receptor (*30–32*). Alignment of the 28-amino acid peptide ghrelin and the 19-amino acid motilin reveals that they share eight amino acids. Although motilin can stimulate the GHS-R at a low level, ghrelin does not activate motilin receptor. After the discovery of ghrelin, the motilin-related peptide

(MTLRP) was identified; the amino acid sequence of MTLRP is identical to that of ghrelin-(1–18) (*33*). The ghrelin receptor is well conserved across all vertebrate species examined, including a number of mammals, bird and fish. This strict conservation suggests that ghrelin and its receptor serve essential physiological functions.

Ghrelin O-acyltransferase

An enzyme that catalyses the acyl-modification of ghrelin was discovered in 2008 by Yang *et al.* (*34*), using an innovative combination of bioinformatics and cell biology (Fig. 2). Using position-specific iterative BLAST and previously reported sequences of membrane-bound *O*-acyltransferases (MBOATs) from diverse species including prokaryotes, plants, humans and mice, they identified 16 MBOATs encoded by the mouse genome. They then isolated clones of all of these and tested them for their ability to catalyse octanoylation of ghrelin expressed in heterologous cell lines. Only one of these enzymes, MBOAT4, was found to be able to octanoylate ghrelin, and this enzyme was renamed ghrelin *O*-acyltransferase (GOAT). Distribution of this enzyme is limited to the gastrointestinal tract and testis, the peripheral tissues that express ghrelin. The optimum temperature of GOAT is 37–50°C, and its optimum pH range is pH 7–8 (*35*).

The origin of the modified medium-chain fatty acids (MCFAs) has not been determined. However, it is known that orally ingested MCFAs are directly utilized for acyl-modification of ghrelin (*36*). Ingestion of either MCFAs or medium-chain triacylglycerols (MCTs) specifically increases production of acyl-modified ghrelin without changing the total (acyl- and des-acyl-) ghrelin level. When mice ingest either MCFAs or MCTs, the acyl group attached to nascent ghrelin molecules corresponds to those of the ingested MCFAs or MCTs. Moreover, *n*-heptanoyl (C7:0) ghrelin, an unnatural form of ghrelin, can be produced in the stomach of mice following ingestion of *n*-heptanoic acid or glyceryl triheptanoate. Thus, it is clear that ingested fatty acids are directly utilized for acyl-modification of ghrelin (*17*).

Recently, Barnett *et al.* (*37*) described the design, synthesis and characterization of GO-CoA-Tat, a peptide-based bisubstrate analog that antagonizes GOAT. GO-CoA-Tat potently inhibits GOAT *in vitro*, in cultured cells and in mice. Intraperitoneal administration of GO-CoA-Tat in the concentration of 8 μmol/kg improves glucose tolerance in 2.5 g/kg of intraperitoneal glucose tolerance test. Moreover, the body weight gain in wild-type mice given MCT diet reduces by treatment with 11 μmol/kg GO-CoA-Tat for 1 month but not ghrelin-deficient mice; thus, its beneficial metabolic effects are due specifically to GOAT inhibition. GOAT is therefore, a useful target for future development of therapeutic compounds.

Obestatin

In 2005, Zhang *et al.* (*38*) used a bioinformatics approach to identify a 23-amino acid peptide derived from the ghrelin peptide precursor; this discovery brought exciting new insights to the gut peptide field. The authors named this peptide 'obestatin' because obestatin has the ability to inhibit food intake in mice by intraperitoneal or intracerebroventricular injection. In addition, the authors reported that peripheral injection of obestatin inhibited jejunal contraction, suppression of gastric emptying and decreased body-weight gain (*39–41*). However, their findings could not be reproduced by several groups, and must therefore be interpreted with caution.

Distribution and Regulation of Ghrelin

The acyl-modification of ghrelin is easily cleaved during sample extraction, and peptide samples are easily digested by a wide range of cellular proteases. Furthermore, in order to correctly measure the plasma concentration of ghrelin, it is necessary to use EDTA and aprotinin when collecting blood samples, and plasma must be collected into 1/10 volume of 1 N HCl (*19*, *42*). If the treated plasma samples are kept at −20 to −80°C, they are stable for at least 6–12 months. When measuring the tissue concentration of ghrelin, it is sufficient to inactivate proteases by boiling the tissues in water for 5–10 min (*43*, *44*). In human, the normal ghrelin concentration of plasma samples is 10–20 fmol/ml for *n*-octanoyl ghrelin and 100–150 fmol/ml for total ghrelin, including both acyl-modified and des-acyl ghrelins (*17*, *45*, *46*). In rats, ghrelin concentration in the stomach is 377.3 ± 55.8 fmol/mg for *n*-octanoyl ghrelin and 1779.8 ± 533.9 fmol/mg for total ghrelin (*17*, *19*). Thus, the concentration of *n*-octanoyl ghrelin is 10–20% that of des-acyl ghrelin.

Ghrelin is present in X/A-like cells, which account for ~20% of the endocrine cell population in adult oxyntic glands (*47*). Ghrelin-immunoreactive cells are also found in the duodenum, jejunum, ileum and colon. In the intestine, ghrelin concentration gradually decreases from the duodenum to the colon. Ghrelin is also secreted from other organs such as hypothalamus and pancreas of rats. In addition, ghrelin mRNA is expressed in various organs (*48*, *49*).

Several cell lines express ghrelin. TT cells, a human thyroid medullary carcinoma cell line, produced ghrelin mRNA; both conditioned medium and cellular extracts of TT cells contain ghrelin peptides (*50*). Cellular extracts of TT cells also contain both *n*-octanoyl ghrelin and des-acyl ghrelin. Other cultured cells that express ghrelin, include the kidney-derived cell line NRK-49F, gastric carcinoid ECC10 cells and the cardiomyocyte cell line HL-1 (*51–53*). Recently, Iwakura *et al.* (*54*) established a ghrelin-producing cell line MGN3-1 from a gastric ghrelin-producing cell tumour derived from transgenic mice in which SV40 Large T antigen was expressed under control of the ghrelin promoter. MGN3-1 cells produce a substantial amount of ghrelin at levels ~5000 times higher than in TT cells. In addition, MGN3-1 cells express two key enzymes: GOAT, for acyl modification and prohormone convertase 1/3 which is required for maturation of ghrelin. Moreover, MGN3-1 cells maintain physiological regulation of ghrelin secretion,

at least in regard to the suppression by somatostatin and insulin, which has been well established in *in vivo* studies. This cell line will be a useful tool for studying both production and secretion of ghrelin, as well as for screening of ghrelin production-modulating drugs.

The most known factor for the regulation of ghrelin secretion is feeding (*45*). Plasma ghrelin concentration increases when fasting, and decreases after food intake. The factors involved in the regulation of ghrelin secretion have not yet been identified. Blood glucose level may be a most probable candidate: oral or intravenous administration of glucose decreases plasma ghrelin concentration (*55*). Because gastric distension by water intake does not change ghrelin concentration, mechanical distension of the stomach alone clearly does not induce ghrelin release (*56, 57*). Plasma ghrelin concentration exhibits a nocturnal increase. Plasma ghrelin concentration is low in obese people and high in lean people (*55, 58–62, 63*). Exogenous GH decreases stomach ghrelin mRNA expression and plasma ghrelin concentration, but does not affect stomach ghrelin stores (*64*).

There may be a relationship between sequence variation in the ghrelin gene and obesity (*65–67*). In humans, two polymorphisms have been reported: Arg51Gln and Leu72Met. For both polymorphisms, allelic frequencies are similar between obese patients and controls. However, obese patients with the Met72 allele became obese earlier than patients homozygous for the wild-type Leu72 allele, suggesting that the polymorphism may affect ghrelin's activity. The Arg51Gln mutation changes the sequence of the COOH-terminal processing site of the ghrelin peptide, within its precursor protein, from Pro-Arg to Pro-Gln; this mutation prevents the normal cleavage necessary to produce mature ghrelin.

Physiological Functions of Ghrelin

GH-releasing activity by ghrelin

Ghrelin is a hormone that has a lot of physiological functions (Table 1). One of its primary functions involves its strong GH-releasing activity (*1, 68–72*). The maximal stimulation effected by ghrelin is two to three times greater than that of GHRH, in both rats and human. GH release reaches its peak ~5–15 min after intravenous ghrelin injection. A single intracerebroventricular administration of ghrelin also increases rat plasma GH concentration (*70*). There are several models regarding the mechanism of ghrelin's stimulatory effect on GH secretion. Ghrelin stimulates GH release from primary pituitary cells, indicating that ghrelin can act directly on the pituitary (*1*). On the other hand, the involvement of the hypothalamus in ghrelin-mediated stimulation of GH release has also been suggested. Furthermore, the induction of GH release after ghrelin injection is dramatically decreased when the vagus nerve is cut, indicating that the vagus nerve is required for the maximal stimulatory effects of ghrelin (*73, 74*). A synergistic effect of ghrelin and GHRH is also important. Co-administration of ghrelin and GHRH results in more GH release than does either GHRH or ghrelin alone (*69, 75*). This finding implies that GHRH is necessary for GH release to be maximally effective in inducing GH release.

Appetite regulation by ghrelin

Ghrelin is only a hunger signal from peripheral tissues. Intravenous and subcutaneous injections of ghrelin increase food intake; likewise, peripherally injected ghrelin stimulates hypothalamic neurons and food intake (*76–81*). Because the rate at which peripheral ghrelin passes the blood–brain barrier has shown to be very low, peripheral ghrelin must activate the appropriate hypothalamic regions via an indirect pathway.

Table I. Physiological functions of ghrelin in human or rats.

Functions	Effects	Organs	Species	References
Pituitary hormone secretions				
GH	↑	pituitary	humans, rats	(*1, 68–72*)
PRL	↑ (weak)	pituitary	humans	(*72*)
ACTH	↑ (weak)	pituitary	humans	(*72*)
Appetite regulations				
Food intake	↑		humans, rats	(*76, 78, 80, 81*)
AMPK activity	↑	hypothalamus	rats	(*98*)
Lipid metabolisms				
Adiposity	↑		rats	(*99*)
Triglyceride	↑	white adipose tissue, liver	rats	(*100*)
Glucose metabolisms				
Blood glucose	↑		humans	(*96*)
Insulin	↓	Pancreas	humans	(*96*)
Cardiovascular functions				
Blood pressure	↓		humans, rats	(*89, 90*)
Cardiac output	↑		rats	(*101*)
Gastric functions				
Gastric acid secretion	↑	Stomach	rats	(*102*)
Gastric movement	↑	Stomach	rats	(*88*)
Bone metabolism				
Osteoblast differenciation	↑	Bone	rats	(*103*)
Bone mineral density	↑	Bone	rats	(*103*)

↑, stimulate; ↓, decrease.

The localization of ghrelin receptors on vagal afferent neurons in the rat nodose ganglion suggests that ghrelin signals from the stomach are transmitted to the brain via the vagus nerve (*73*, *82*). As noted above, vagotomy actually inhibits the ability of ghrelin to stimulate food intake (*73*). A similar effect is also observed when capsaicin, a specific afferent neurotoxin, is applied to vagus nerve terminals to induce sensory denervation. Moreover, fasting-induced elevation of plasma ghrelin is completely abolished by sub-diaphragmatic vagotomy or atropine treatment (*74*). In summary, ghrelin is secreted primarily from stomach in response to hunger and starvation, circulates in the blood and serves as a peripheral signal, informing the central nervous system (via vagus nerve) to stimulate feeding.

Ghrelin is also identified in hypothalamus. Ghrelin-containing neurons are found in the arcuate nucleus (ARC) of the hypothalamus, a region involved in appetite regulation (*1*). In fact, intracerebroventricular injection of ghrelin increases cumulative food intake and decreases energy expenditure, resulting in body weight gain (*77*, *79*, *83–85*). This orexigenic effect of hypothalamic ghrelin is regulated through a neuronal network involving food intake. To stimulate the release of the orexigenic peptides, ghrelin-containing neurons send efferent fibers onto neuropeptide Y (NPY)- and agouti-related protein (AgRP)-expressing neurons. On the other hand, to suppress the release of the anorexigenic peptide, ghrelin-containing neurons send efferent fibers onto pro-opiomelanocortin (POMC) neurons (*86*). The ARC is also a target of leptin, an appetite-suppressing hormone produced in adipose tissues (*87*). Leptin directly inhibits appetite-stimulating effects of NPY and AgRP, whereas hypothalamic ghrelin augments NPY gene expression and blocked leptin-induced feeding reduction. Thus, ghrelin and leptin have a competitive interaction in feeding regulation.

Other functions of ghrelin

Intravenous administration of ghrelin increases gastric acid secretion and stimulates gastric motility in a dose-dependent manner (*88*). The maximum response to ghrelin, in terms of gastric acid secretion, is almost as high as that elicited by subcutaneous treatment with histamine (3 mg/kg). These responses to ghrelin were abolished by pre-treatment with either atropine or bilateral cervical vagotomy, but not by a histamine H2-receptor antagonist.

An intravenous bolus of human ghrelin decreased mean arterial pressure without changing the heart rate (*89*, *90*). The decrease in mean arterial pressure induced by ghrelin seems not to occur through direct action on the circulatory system, but by its action on the nucleus of the solitary tract (*91*, *92*). Microinjection of ghrelin into this nucleus significantly decreased the mean arterial pressure and heart rate. This injection also suppressed sympathetic activity.

There are many reports on the regulation of insulin secretion by ghrelin (*48*, *93–95*). Date *et al.* (*48*) reported that ghrelin stimulates insulin release in the presence of high levels of glucose (8.3 mM) that could independently cause insulin release from cultured islet cells. In contrast, ghrelin had no effect on insulin release in the context of a basal level of glucose (2.8 mM). On the other hand, ghrelin reduces insulin secretion and induces hyperglycaemia in humans (*96*). Thus, the regulation of insulin secretion by ghrelin is closely related to the blood glucose level. Ghrelin originating from pancreatic islets may be a major regulator of insulin secretion. Antagonism of the pancreatic ghrelin can enhance insulin release to meet increased demand for insulin in high-fat diet-induced obesity of mice (*97*). Since there is a difference of a result among researchers about the role of the ghrelin on insulin secretion, further research is expected.

After the discovery of ghrelin, it was realized that the stomach is an important organ not only for digestive function, but also for the regulation of energy metabolism and the secretion of GH. In addition, the novel octanoylated structure of ghrelin represented a new finding in biochemistry. The newly identified enzyme that catalyses the acyl-modification of ghrelin, GOAT, strongly provides the secretory machinery of the ghrelin and may herald new progress in our understanding of fatty acid metabolism. The mechanism of ghrelin synthesis still remains unclear, but will hopefully be elucidated by future research.

Funding

This work was supported by Grant in Aid for Scientific Research on Innovative Areas (Research in a proposed research area). "Molecular Basis and Disorders of Control of Appetite and Fat Accumulation" (to M.K.); Grants-in-Aid from the Japanese Ministry of Education, Science and Culture, by Research Grants for Intractable Diseases from the Japanese Ministry of Health and Welfare (to M.K.); Grant-in-Aid for Scientific Research (B) from The Ministry of Education, Culture, Sports, Science and Technology (MEXT) (to M.K.); Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (JSPS) (to T.S.); a grant from the Takeda Scientific Foundation in Japan (to M.K. and T.S.), and the Foundation for Growth Science (to T.S.).

Conflict of interest

None declared.

References

1. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* **402**, 656–660
2. Bowers, C.Y., Momany, F., Reynolds, G.A., Chang, D., Hong, A., and Chang, K. (1980) Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. *Endocrinology* **106**, 663–667
3. Bowers, C.Y., Momany, F.A., Reynolds, G.A., and Hong, A. (1984) On the in Vitro and in Vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. *Endocrinology* **114**, 1537–1545
4. Cheng, K., Chan, W.W., Butler, B., Wei, L., Schoen, W.R., Wyvratt, M.J. Jr., Fisher, M.H., and Smith, R.G. (1993) Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel

non-peptidyl Gh secretagogue. *Endocrinology* **132**, 2729–2731

5. Patchett, A.A., Nargund, R.P., Tata, J.R., Chen, M.H., Barakat, K.J., Johnston, D.B., Cheng, K., Chan, W.W., Butler, B., Hickey, G., Jacks, T., Schleim, K., Pong, S.-S., Chaung, L.-Y.P., Chen, H.Y., Frazier, E., Leung, K.H., Chiu, S.-H.L., and Smith, R.G. (1995) Design and biological activities of L-163,191 (Mk-0677): a potent, orally active growth hormone secretagogue. *Proc. Natl Acad. Sci. USA* **92**, 7001–7005
6. Akman, M.S., Girard, M., O'Brien, L.F., Ho, A.K., and Chik, C.L. (1993) Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-Beta Nal-Ala-Trp-D-Phe-Lys-Nh2) in rat anterior pituitary cells. *Endocrinology* **132**, 1286–1291
7. Blake, A.D. and Smith, R.G. (1991) Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-Nh2 stimulate growth hormone release through distinct receptor sites. *J. Endocrinol.* **129**, 11–19
8. Cheng, K., Chan, W.W., Barreto, A. Jr., Convey, E.M., and Smith, R.G. (1989) The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-Nh2 on growth hormone (Gh)-releasing factor-stimulated Gh release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture. *Endocrinology* **124**, 2791–2798
9. Cheng, K., Chan, W.W., Butler, B., Barreto, A. Jr., and Smith, R.G. (1991) Evidence for a role of protein kinase-C in His-D-Trp-Ala-Trp-D-Phe-Lys-Nh2-induced growth hormone release from rat primary pituitary cells. *Endocrinology* **129**, 3337–3342
10. Popovic, V., Micic, D., Damjanovic, S., Djurovic, M., Simic, M., Gligorovic, M., Dieguez, C., and Casanueva, F.F. (1996) Evaluation of pituitary Gh reserve with Ghrp-6. *J. Pediatr. Endocrinol. Metab.* **9 (Suppl. 3)**, 289–298
11. Howard, A.D., Feighner, S.D., Cully, D.F., Arena, J.P., Liberator, P.A., Rosenblum, C.I., Hamelin, M., Hreniuk, D.L., Palyha, O.C., Anderson, J., Paress, P.S., Diaz, C., Chou, M., Liu, K.K., McKee, K.K., Pong, S.S., Chaung, L.Y., Elbrecht, A., Dashkevicz, M., Heavens, R., Rigby, M., Sirinathsinghji, D.J., Dean, D.C., Melillo, D.G., Patchett, A.A., Nargund, R., Griffin, P.R., DeMartino, J.A., Gupta, S.K., Schaeffer, J.M., Smith, R.G., and Van der Ploeg, L.H. (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. *Science* **273**, 974–977
12. Bennett, P.A., Thomas, G.B., Howard, A.D., Feighner, S.D., van der Ploeg, L.H., Smith, R.G., and Robinson, I.C. (1997) Hypothalamic growth hormone secretagogue-receptor (Ghs-R) expression is regulated by growth hormone in the rat. *Endocrinology* **138**, 4552–4557
13. Guan, X.M., Yu, H., Palyha, O.C., McKee, K.K., Feighner, S.D., Sirinathsinghji, D.J., Smith, R.G., Van der Ploeg, L.H., and Howard, A.D. (1997) Distribution of MRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. *Brain Res. Mol. Brain Res.* **48**, 23–29
14. Smith, R.G., Van der Ploeg, L.H., Howard, A.D., Feighner, S.D., Cheng, K., Hickey, G.J., Wyvratt, M.J. Jr., Fisher, M.H., Nargund, R.P., and Patchett, A.A. (1997) Peptidomimetic regulation of growth hormone secretion. *Endocr. Rev.* **18**, 621–645
15. Kanamoto, N., Akamizu, T., Tagami, T., Hataya, Y., Moriyama, K., Takaya, K., Hosoda, H., Kojima, M., Kangawa, K., and Nakao, K. (2004) Genomic structure and characterization of the 5'-flanking region of the human ghrelin gene. *Endocrinology* **145**, 4144–4153
16. Tanaka, M., Hayashida, Y., Iguchi, T., Nakao, N., Nakai, N., and Nakashima, K. (2001) Organization of the mouse ghrelin gene and promoter: occurrence of a short noncoding first exon. *Endocrinology* **142**, 3697–3700
17. Kojima, M. and Kangawa, K. (2005) Ghrelin: structure and function. *Physiol. Rev.* **85**, 495–522
18. Hosoda, H., Kojima, M., Matsuo, H., and Kangawa, K. (2000) Purification and characterization of rat Des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. *J. Biol. Chem.* **275**, 21995–22000
19. Hosoda, H., Kojima, M., Matsuo, H., and Kangawa, K. (2000) Ghrelin and Des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. *Biochem. Biophys. Res. Commun.* **279**, 909–913
20. Toshinai, K., Yamaguchi, H., Sun, Y., Smith, R.G., Yamanaka, A., Sakurai, T., Date, Y., Mondal, M.S., Shimbara, T., Kawagoe, T., Murakami, N., Miyazato, M., Kangawa, K., and Nakazato, M. (2006) Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. *Endocrinology* **147**, 2306–2314
21. Angeloni, S.V., Glynn, N., Ambrosini, G., Garant, M.J., Higley, J.D., Suomi, S., and Hansen, B.C. (2004) Characterization of the Rhesus monkey ghrelin gene and factors influencing ghrelin gene expression and fasting plasma levels. *Endocrinology* **145**, 2197–2205
22. Tomasetto, C., Wendling, C., Rio, M.C., and Poitras, P. (2001) Identification of Cdna encoding motilin related peptide/ghrelin precursor from dog fundus. *Peptides* **22**, 2055–2059
23. Kaiya, H., Van Der Geyten, S., Kojima, M., Hosoda, H., Kitajima, Y., Matsumoto, M., Geelissen, S., Darras, V.M., and Kangawa, K. (2002) Chicken ghrelin: purification, Cdna cloning, and biological activity. *Endocrinology* **143**, 3454–3463
24. Kaiya, H., Kojima, M., Hosoda, H., Koda, A., Yamamoto, K., Kitajima, Y., Matsumoto, M., Minamitake, Y., Kikuyama, S., and Kangawa, K. (2001) Bullfrog ghrelin is modified by N-Octanoic acid at its third threonine residue. *J. Biol. Chem.* **276**, 40441–40448
25. Kaiya, H., Kojima, M., Hosoda, H., Moriyama, S., Takahashi, A., Kawauchi, H., and Kangawa, K. (2003) Peptide purification, complementary deoxyribonucleic acid (DNA) and genomic dna cloning, and functional characterization of ghrelin in rainbow trout. *Endocrinology* **144**, 5215–5226
26. Kaiya, H., Kojima, M., Hosoda, H., Riley, L.G., Hirano, T., Grau, E.G., and Kangawa, K. (2003) Amidated fish ghrelin: purification, Cdna cloning in the Japanese eel and its biological activity. *J. Endocrinol.* **176**, 415–423
27. Kaiya, H., Kojima, M., Hosoda, H., Riley, L.G., Hirano, T., Grau, E.G., and Kangawa, K. (2003) Identification of Tilapia ghrelin and its effects on growth hormone and prolactin release in the Tilapia, Oreochromis Mossambicus. *Comp. Biochem. Physiol. B Biochem. Mol. Biol.* **135**, 421–429

28. Parhar, I.S., Sato, H., and Sakuma, Y. (2003) Ghrelin gene in cichlid fish is modulated by sex and development. *Biochem. Biophys. Res. Commun.* **305**, 169–175
29. Unniappan, S., Lin, X., Cervini, L., Rivier, J., Kaiya, H., Kangawa, K., and Peter, R.E. (2002) Goldfish ghrelin: molecular characterization of the complementary deoxyribonucleic acid, partial gene structure and evidence for its stimulatory role in food intake. *Endocrinology* **143**, 4143–4146
30. Feighner, S.D., Tan, C.P., McKee, K.K., Palyha, O.C., Hreniuk, D.L., Pong, S.S., Austin, C.P., Figueroa, D., MacNeil, D., Cascieri, M.A., Nargund, R., Bakshi, R., Abramovitz, M., Stocco, R., Kargman, S., O'Neill, G., Van Der Ploeg, L.H., Evans, J., Patchett, A.A., Smith, R.G., and Howard, A.D. (1999) Receptor for motilin identified in the human gastrointestinal system. *Science* **284**, 2184–2188
31. Inui, A. (2001) Ghrelin: an orexigenic and somatotrophic signal from the stomach. *Nat. Rev. Neurosci.* **2**, 551–560
32. Smith, R.G., Leonard, R., Bailey, A.R., Palyha, O., Feighner, S., Tan, C., McKee, K.K., Pong, S.S., Griffin, P., and Howard, A. (2001) Growth hormone secretagogue receptor family members and ligands. *Endocrine* **14**, 9–14
33. Tomasetto, C., Karam, S.M., Ribieras, S., Masson, R., Lefebvre, O., Staub, A., Alexander, G., Chenard, M.P., and Rio, M.C. (2000) Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. *Gastroenterology* **119**, 395–405
34. Yang, J., Brown, M.S., Liang, G., Grishin, N.V., and Goldstein, J.L. (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. *Cell* **132**, 387–396
35. Ohgusu, H., Shirouzu, K., Nakamura, Y., Nakashima, Y., Ida, T., Sato, T., and Kojima, M. (2009) Ghrelin O-acyltransferase (goat) has a preference for N-hexanoyl-coa over N-octanoyl-coa as an acyl donor. *Biochem. Biophys. Res. Commun.* **386**, 153–158
36. Nishi, Y., Hiejima, H., Hosoda, H., Kaiya, H., Mori, K., Fukue, Y., Yanase, T., Nawata, H., Kangawa, K., and Kojima, M. (2005) Ingested medium-chain fatty acids are directly utilized for the acyl modification of ghrelin. *Endocrinology* **146**, 2255–2264
37. Barnett, B.P., Hwang, Y., Taylor, M.S., Kirchner, H., Pfluger, P.T., Bernard, V., Lin, Y.Y., Bowers, E.M., Mukherjee, C., Song, W.J., Longo, P.A., Leahy, D.J., Hussain, M.A., Tschop, M.H., Boeke, J.D., and Cole, P.A. Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. *Science* **330**, 1689–1692
38. Zhang, J.V., Ren, P.G., Avsian-Kretchmer, O., Luo, C.W., Rauch, R., Klein, C., and Hsueh, A.J. (2005) Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. *Science* **310**, 996–999
39. Gourcerol, G., Million, M., Adelson, D.W., Wang, Y., Wang, L., Rivier, J., St-Pierre, D.H., and Tache, Y. (2006) Lack of interaction between peripheral injection of Cck and obestatin in the regulation of gastric satiety signaling in rodents. *Peptides* **27**, 2811–2819
40. Holst, B., Egerod, K.L., Schild, E., Vickers, S.P., Cheetham, S., Gerlach, L.O., Storjohann, L., Stidsen, C.E., Jones, R., Beck-Sickinger, A.G., and Schwartz, T.W. (2007) Gpr39 signaling is stimulated by zinc ions but not by obestatin. *Endocrinology* **148**, 13–20
41. Yamamoto, D., Ikeshita, N., Daito, R., Herningtyas, E.H., Toda, K., Takahashi, K., Iida, K., Takahashi, Y., Kaji, H., Chihara, K., and Okimura, Y. (2007) Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of Gh, Prl, Tsh and Acth in rats. *Regul. Pept.* **138**, 141–144
42. Hosoda, H., Doi, K., Nagaya, N., Okumura, H., Nakagawa, E., Enomoto, M., Ono, F., and Kangawa, K. (2004) Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to Desacyl ghrelin in blood samples. *Clin. Chem.* **50**, 1077–1080
43. Kangawa, K. and Matsuo, H. (1984) Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (Alpha-Hanp). *Biochem. Biophys. Res. Commun.* **118**, 131–139
44. Sudoh, T., Kangawa, K., Minamino, N., and Matsuo, H. (1988) A new natriuretic peptide in porcine brain. *Nature* **332**, 78–81
45. Cummings, D.E., Purnell, J.Q., Frayo, R.S., Schmidova, K., Wisse, B.E., and Weigle, D.S. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. *Diabetes* **50**, 1714–1719
46. Tschop, M., Wawarta, R., Riepl, R.L., Friedrich, S., Bidlingmaier, M., Landgraf, R., and Folwaczny, C. (2001) Post-prandial decrease of circulating human ghrelin levels. *J. Endocrinol. Invest.* **24**, RC19–RC21
47. Date, Y., Kojima, M., Hosoda, H., Sawaguchi, A., Mondal, M.S., Suganuma, T., Matsukura, S., Kangawa, K., and Nakazato, M. (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. *Endocrinology* **141**, 4255–4261
48. Date, Y., Nakazato, M., Hashiguchi, S., Dezaki, K., Mondal, M.S., Hosoda, H., Kojima, M., Kangawa, K., Arima, T., Matsuo, H., Yada, T., and Matsukura, S. (2002) Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. *Diabetes* **51**, 124–129
49. Sato, T., Fukue, Y., Teranishi, H., Yoshida, Y., and Kojima, M. (2005) Molecular forms of hypothalamic ghrelin and its regulation by fasting and 2-deoxy-D-glucose administration. *Endocrinology* **146**, 2510–2516
50. Kanamoto, N., Akamizu, T., Hosoda, H., Hataya, Y., Ariyasu, H., Takaya, K., Hosoda, K., Saijo, M., Moriyama, K., Shimatsu, A., Kojima, M., Kangawa, K., and Nakao, K. (2001) Substantial production of ghrelin by a human medullary thyroid carcinoma cell line. *J. Clin. Endocrinol. Metab.* **86**, 4984–4990
51. Iglesias, M.J., Pineiro, R., Blanco, M., Gallego, R., Dieguez, C., Gualillo, O., Gonzalez-Juanatey, J. R., and Lago, F. (2004) Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. *Cardiovasc. Res.* **62**, 481–488
52. Kishimoto, M., Okimura, Y., Nakata, H., Kudo, T., Iguchi, G., Takahashi, Y., Kaji, H., and Chihara, K. (2003) Cloning and characterization of the 5′-flanking region of the human ghrelin gene. *Biochem. Biophys. Res. Commun.* **305**, 186–192
53. Mori, K., Yoshimoto, A., Takaya, K., Hosoda, K., Ariyasu, H., Yahata, K., Mukoyama, M., Sugawara, A., Hosoda, H., Kojima, M., Kangawa, K., and Nakao, K. (2000) Kidney produces a novel acylated peptide, ghrelin. *FEBS Lett.* **486**, 213–216
54. Iwakura, H., Li, Y., Ariyasu, H., Hosoda, H., Kanamoto, N., Bando, M., Yamada, G., Hosoda, K., Nakao, K., Kangawa, K., and Akamizu, T.

Establishment of a novel ghrelin-producing cell line. *Endocrinology* **151**, 2940–2945

55. Shiiya, T., Nakazato, M., Mizuta, M., Date, Y., Mondal, M.S., Tanaka, M., Nozoe, S., Hosoda, H., Kangawa, K., and Matsukura, S. (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. *J. Clin. Endocrinol. Metab.* **87**, 240–244
56. Dzaja, A., Dalal, M.A., Himmerich, H., Uhr, M., Pollmacher, T., and Schuld, A. (2004) Sleep enhances nocturnal plasma ghrelin levels in healthy subjects. *Am. J. Physiol. Endocrinol. Metab.* **286**, E963–E967
57. Yildiz, B.O., Suchard, M.A., Wong, M.L., McCann, S.M., and Licinio, J. (2004) Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. *Proc. Natl Acad. Sci. USA* **101**, 10434–10439
58. Bellone, S., Rapa, A., Vivenza, D., Castellino, N., Petri, A., Bellone, J., Me, E., Broglio, F., Prodam, F., Ghigo, E., and Bona, G. (2002) Circulating ghrelin levels as function of gender, pubertal status and adiposity in childhood. *J. Endocrinol. Invest.* **25**, RC13–RC15
59. Cummings, D.E., Weigle, D.S., Frayo, R.S., Breen, P.A., Ma, M.K., Dellinger, E.P., and Purnell, J. Q. (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. *N. Engl. J. Med.* **346**, 1623–1630
60. Hansen, T.K., Dall, R., Hosoda, H., Kojima, M., Kangawa, K., Christiansen, J.S., and Jorgensen, J.O. (2002) Weight loss increases circulating levels of ghrelin in human obesity. *Clin. Endocrinol.* **56**, 203–206
61. Haqq, A.M., Farooqi, I.S., O'Rahilly, S., Stadler, D.D., Rosenfeld, R.G., Pratt, K.L., LaFranchi, S.H., and Purnell, J.Q. (2003) Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. *J. Clin. Endocrinol. Metab.* **88**, 174–178
62. Rosicka, M., Krsek, M., Matoulek, M., Jarkovska, Z., Marek, J., Justova, V., and Lacinova, Z. (2003) Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels. *Physiol. Res.* **52**, 61–66
63. Tschop, M., Weyer, C., Tataranni, P.A., Devanarayan, V., Ravussin, E., and Heiman, M.L. (2001) Circulating ghrelin levels are decreased in human obesity. *Diabetes* **50**, 707–709
64. Qi, X., Reed, J., Englander, E.W., Chandrashekar, V., Bartke, A., and Greeley, G.H. Jr. (2003) Evidence that growth hormone exerts a feedback effect on stomach ghrelin production and secretion. *Exp. Biol. Med.* **228**, 1028–1032
65. Miraglia del Giudice, E., Santoro, N., Cirillo, G., Raimondo, P., Grandone, A., D'Aniello, A., Di Nardo, M., and Perrone, L. (2004) Molecular screening of the ghrelin gene in Italian obese children: the Leu72met variant is associated with an earlier onset of obesity. *Int. J. Obes. Relat. Metab. Disord.* **28**, 447–450
66. Poykko, S., Ukkola, O., Kauma, H., Savolainen, M.J., and Kesaniemi, Y.A. (2003) Ghrelin Arg51gln mutation is a risk factor for type 2 diabetes and hypertension in a random sample of middle-aged subjects. *Diabetologia* **46**, 455–458
67. Ukkola, O., Ravussin, E., Jacobson, P., Snyder, E.E., Chagnon, M., Sjostrom, L., and Bouchard, C. (2001) Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. *J. Clin. Endocrinol. Metab.* **86**, 3996–3999
68. Arvat, E., Di Vito, L., Broglio, F., Papotti, M., Muccioli, G., Dieguez, C., Casanueva, F.F., Deghenghi, R., Camanni, F., and Ghigo, E. (2000) Preliminary evidence that ghrelin, the natural Gh secretagogue (Ghs)-receptor ligand, strongly stimulates Gh secretion in humans. *J. Endocrinol. Invest.* **23**, 493–495
69. Arvat, E., Maccario, M., Di Vito, L., Broglio, F., Benso, A., Gottero, C., Papotti, M., Muccioli, G., Dieguez, C., Casanueva, F.F., Deghenghi, R., Camanni, F., and Ghigo, E. (2001) Endocrine activities of ghrelin, a natural growth hormone secretagogue (Ghs), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl Ghs, and Gh-releasing hormone. *J. Clin. Endocrinol. Metab.* **86**, 1169–1174
70. Date, Y., Murakami, N., Kojima, M., Kuroiwa, T., Matsukura, S., Kangawa, K., and Nakazato, M. (2000) Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. *Biochem. Biophys. Res. Commun.* **275**, 477–480
71. Peino, R., Baldelli, R., Rodriguez-Garcia, J., Rodriguez-Segade, S., Kojima, M., Kangawa, K., Arvat, E., Ghigo, E., Dieguez, C., and Casanueva, F.F. (2000) Ghrelin-induced growth hormone secretion in humans. *Eur. J. Endocrinol.* **143**, R11–R14
72. Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu, A., Ogawa, Y., Hosoda, K., Akamizu, T., Kojima, M., Kangawa, K., and Nakao, K. (2000) Ghrelin strongly stimulates growth hormone release in humans. *J. Clin. Endocrinol. Metab.* **85**, 4908–4911
73. Date, Y., Murakami, N., Toshinai, K., Matsukura, S., Niijima, A., Matsuo, H., Kangawa, K., and Nakazato, M. (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. *Gastroenterology* **123**, 1120–1128
74. Williams, D.L., Grill, H.J., Cummings, D.E., and Kaplan, J.M. (2003) Vagotomy dissociates short- and long-term controls of circulating ghrelin. *Endocrinology* **144**, 5184–5187
75. Hataya, Y., Akamizu, T., Takaya, K., Kanamoto, N., Ariyasu, H., Saijo, M., Moriyama, K., Shimatsu, A., Kojima, M., Kangawa, K., and Nakao, K. (2001) A low dose of ghrelin stimulates growth hormone (Gh) release synergistically with Gh-releasing hormone in humans. *J. Clin. Endocrinol. Metab.* **86**, 4552
76. Hewson, A.K. and Dickson, S.L. (2000) Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. *J. Neuroendocrinol.* **12**, 1047–1049
77. Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., and Matsukura, S. (2001) A role for ghrelin in the central regulation of feeding. *Nature* **409**, 194–198
78. Ruter, J., Kobelt, P., Tebbe, J.J., Avsar, Y., Veh, R., Wang, L., Klapp, B.F., Wiedenmann, B., Tache, Y., and Monnikes, H. (2003) Intraperitoneal injection of ghrelin induces fos expression in the paraventricular nucleus of the hypothalamus in rats. *Brain Res.* **991**, 26–33
79. Tschop, M., Smiley, D.L., and Heiman, M.L. (2000) Ghrelin induces adiposity in rodents. *Nature* **407**, 908–913
80. Wang, L., Saint-Pierre, D.H., and Tache, Y. (2002) Peripheral ghrelin selectively increases Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. *Neurosci. Lett.* **325**, 47–51
81. Wren, A.M., Seal, L.J., Cohen, M.A., Brynes, A.E., Frost, G.S., Murphy, K.G., Dhillo, W.S., Ghatei,